Clinical trial • Phase I • Oncology

INCB123667 for Advanced or metastatic solid tumors

Phase I trial of INCB123667 for Advanced or metastatic solid tumors. open-label, none/not specified-controlled. 369 participants.

Overview

Trial Therapeutic Area
Oncology
Trial Disease
Advanced or metastatic solid tumors
Trial Stage
Phase I

Key dates

Initial CTIS Submission Date
21-05-2024
First CTIS Authorization Date
21-06-2024

Trial design

open-label, none/not specified-controlled Phase I trial across 11 sites in France, Italy, Netherlands.

Open Label
Yes
Comparator
None/Not specified
Target Sample Size
369

Recruitment

Planned Sample Size
369
Recruitment Window Months
48

Geography

Total Number Of Sites
11
Total Number Of Participants
235

France

Earliest CTIS Part Ii Submission Date
26-03-2024
Latest Decision Or Authorization Date
25-06-2024
Processing Time Days
91
Number Of Sites
4
Number Of Participants
50

Sites

Site Name
Institut Universitaire Du Cancer Toulouse-Oncopole
Department Name
Medical Oncology
Principal Investigator Name
Carlos Gomez-Roca
Principal Investigator Email
gomez-roca.carlos@iuct-oncopole.fr
Contact Person Name
Carlos Gomez-Roca
Site Name
Centre Leon Berard
Department Name
Medical Oncology
Principal Investigator Name
Philippe Cassier
Principal Investigator Email
philippe.cassier@lyon.unicancer.fr
Contact Person Name
Philippe Cassier
Site Name
Institut Gustave Roussy
Department Name
Department of Medicine
Principal Investigator Name
Kaïssa Ouali
Principal Investigator Email
kaissa.ouali@gustaveroussy.fr
Contact Person Name
Kaïssa Ouali
Contact Person Email
kaissa.ouali@gustaveroussy.fr
Site Name
Institut Bergonie
Department Name
Medical Oncology
Principal Investigator Name
Antoine Italiano
Principal Investigator Email
a.italiano@bordeaux.unicancer.fr
Contact Person Name
Antoine Italiano

Italy

Earliest CTIS Part Ii Submission Date
26-03-2024
Latest Decision Or Authorization Date
09-09-2024
Processing Time Days
167
Number Of Sites
5
Number Of Participants
160

Sites

Site Name
Humanitas Mirasole S.p.A.
Department Name
Oncology and Hematology
Principal Investigator Name
Matteo Simonelli
Principal Investigator Email
matteo.simonelli@hunimed.eu
Contact Person Name
Matteo Simonelli
Contact Person Email
matteo.simonelli@hunimed.eu
Site Name
Centro Ricerche Cliniche Di Verona S.r.l.
Department Name
Oncology
Principal Investigator Name
Davide Melisi
Principal Investigator Email
davide.melisi@univr.it
Contact Person Name
Davide Melisi
Contact Person Email
davide.melisi@univr.it
Site Name
Istituto Nazionale Dei Tumori
Department Name
Medical Oncology Department
Principal Investigator Name
Silvia Damian
Principal Investigator Email
silvia.damian@istitutotumori.mi.it
Contact Person Name
Silvia Damian
Site Name
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Department Name
Gynecologic Oncology Unit
Principal Investigator Name
Vanda Salutari
Principal Investigator Email
vanda.salutari@policlinicogemelli.it
Contact Person Name
Vanda Salutari
Site Name
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Department Name
UOC Fase 1
Principal Investigator Name
Gennaro Daniele
Principal Investigator Email
gennaro.daniele@policlinogemelli.it
Contact Person Name
Gennaro Daniele

Netherlands

Earliest CTIS Part Ii Submission Date
26-03-2024
Latest Decision Or Authorization Date
21-06-2024
Processing Time Days
87
Number Of Sites
2
Number Of Participants
25

Sites

Site Name
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Department Name
Medical Oncology
Principal Investigator Name
Ingrid Boere
Principal Investigator Email
i.boere@erasmusmc.nl
Contact Person Name
Ingrid Boere
Contact Person Email
i.boere@erasmusmc.nl
Site Name
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
Department Name
Internal Oncology
Principal Investigator Name
Frans Opdam
Principal Investigator Email
f.opdam@nki.nl
Contact Person Name
Frans Opdam
Contact Person Email
f.opdam@nki.nl

Sponsor

Primary sponsor

Full Name
Incyte Corp.
Organisation Type
Pharmaceutical company
Country Of Registered Address
United States

Investigational products

Investigational Product Name
INCB123667
Combination Treatment
Yes

Related trials

Other published trials that may interest you.